(NASDAQ: ERAS) Erasca's forecast annual revenue growth rate of N/A is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 55.22%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 10.26%.
Erasca's revenue in 2025 is $0.On average, 2 Wall Street analysts forecast ERAS's revenue for 2027 to be $9,483,328,400, with the lowest ERAS revenue forecast at $8,768,311,048, and the highest ERAS revenue forecast at $10,198,345,752. On average, 1 Wall Street analysts forecast ERAS's revenue for 2028 to be $32,861,336,312, with the lowest ERAS revenue forecast at $32,861,336,312, and the highest ERAS revenue forecast at $32,861,336,312.
In 2029, ERAS is forecast to generate $40,112,076,854 in revenue, with the lowest revenue forecast at $16,484,492,759 and the highest revenue forecast at $63,739,660,950.